[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100610117":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":31,"centralContacts":36,"locations":46,"responsibleParty":64,"collaborators":68,"id":72,"slug":73,"hasResults":74,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":10,"eligibilityCriteria":78,"healthyVolunteers":74,"sex":79,"minAge":80,"maxAge":10,"enrollmentInfo":81,"targetDuration":10,"studyType":84,"phases":10,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":48,"whyStopped":10,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":100},{"fullName":5,"class":6},"University of Pittsburgh","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"fianlimab + cemiplimab",null,"Patients who received fianlimab + cemiplimab treatment under protocol NCT06246916.",[13],"Drug: Fianlimab + Cemiplimab",{"label":15,"type":10,"description":16,"interventionNames":17},"Opdualag (relatlimab + nivolumab)","Patients who received Opdualag (relatlimab + nivolumab) under protocol NCT06246916.",[18],"Drug: Relatlimab + Nivolumab",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DRUG","Fianlimab + Cemiplimab","Patients treated with Fianlimab 1600 mg + Cemiplimab 350 mg under protocol NCT06246916",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"Relatlimab + Nivolumab","Patients treated with Relatlimab 160 mg + Nivolumab 480 mg under protocol NCT06246916",[15],[30],"Opdualag",[32],{"name":33,"affiliation":34,"role":35},"John M Kirkwood, MD","UPMC Hillman Cancer Center","PRINCIPAL_INVESTIGATOR",[37,42],{"name":38,"role":39,"phone":40,"phoneExt":10,"email":41},"Danielle L Bednarz, RN","CONTACT","4126231191","bednarzdl@upmc.edu",{"name":43,"role":39,"phone":44,"phoneExt":10,"email":45},"Amy Rose, RN","4126478587","kennaj@upmc.edu",[47],{"facility":34,"status":48,"city":49,"state":50,"zip":51,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"RECRUITING","Pittsburgh","Pennsylvania","15232","United States","US",{"type":55,"coordinates":56},"Point",[57,58],-79.99589,40.44062,{"lat":58,"lon":57},[61,62,63],{"name":38,"role":39,"phone":40,"phoneExt":10,"email":41},{"name":43,"role":39,"phone":44,"phoneExt":10,"email":45},{"name":33,"role":35,"phone":10,"phoneExt":10,"email":10},{"type":65,"investigatorFullName":66,"investigatorTitle":67,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","John Kirkwood","Professor of Medicine",[69],{"name":70,"class":71},"Regeneron Pharmaceuticals","INDUSTRY","100610117","opdualag-vs-cemiplimabfianlimab-in-relation-to-the-immunological-response-in-tumor-and-peripheral-blood-in-unresectable-or-metastatic-melanoma-100610117",false,"NCT07223411","Opdualag vs. Cemiplimab\u002FFianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma","Dose-response Analysis of Nivolumab\u002FRelatlimab in the Fixed-dosed Combination 'Opdualag' vs. Cemiplimab\u002FFianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood for Participants With Unresectable or Metastatic Melanoma: A Corollary Study of HCC 24-056 (NCT06246916)","Inclusion Criteria:\n\n1. Study participants who meet inclusion criteria for the HCC 24-056 study will be eligible for this study.\n2. Participants must be willing to provide additional samples beyond what is required of them in HCC 24-056. These include:\n\n   1. 3 additional tumor biopsies\n   2. 3 additional blood draws\n3. Participants must have biopsiable non-target disease amenable to at least 3 biopsies.\n4. Must have the ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1\\. Study participants who do not qualify to enroll in the HCC 24-056 study will not be eligible for this study.\n\n\\-","ALL","18 Years",{"count":82,"type":83},20,"ESTIMATED","OBSERVATIONAL","This translational study will examine the immune effector responses of patients who received a two-drug combination for first line therapy by examining tumor and peripheral blood of participants with unresectable locally advanced or metastatic melanoma.",[87],"Locally Advanced Melanoma",[89,90],"immune checkpoint inhibitor","immunological response","2025-11-20",{"date":93,"type":94},"2025-11-26","ACTUAL",{"date":96,"type":94},"2025-11-19",{"date":98,"type":83},"2031-11-01",{"name":66,"class":6},1]